Antifungal resistance and predominance of virulence determinants among Candida albicans isolated from various clinical specimens | ||||
| Archives of Pharmaceutical Sciences Ain Shams University | ||||
| Article 2, Volume 3, Issue 1, January 2019, Page 11-20 PDF (994.06 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/aps.2019.20210 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Houdaii H. El-Houssaini1; Walid Faisal Elkhatib   2; Omnia M. Elnabawy3; Hebatallah A. Nasser1
| ||||
| 1Department of Microbiology and Public Health, Faculty of Pharmacy, Heliopolis University for Sustainable Development, 3 Cairo-Belbeis Road, El Horreya P.O 11788, Cairo, Egypt | ||||
| 2Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, African Union Organization St., Abbassia 11566, Cairo, Egypt | ||||
| 3Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Abbassia square, Cairo, Egypt | ||||
| Abstract | ||||
| Candida albicans remains the most common cause of hospital-acquired fungal infections due to its virulence determinants. Resistance to antifungal therapy has increased dramatically, narrowing the few available therapeutic options due to their potential toxicity. However, the association between C. albicans virulence determinants and resistance profiles needs further investigation. C. albicans (n= 25) isolated from various clinical samples were identified. Antibiogram analysis of the tested isolates against different antifungal agents was performed and their minimum inhibitory concentrations (MICs) were verified. Virulence determinants including extracellular hydrolytic enzymes, biofilm formation, and cell surface hydrophobicity (CSH) were investigated. Correlations between virulence determinants and resistance profiles of the experimented isolates, in addition to their potential association with the source of clinical specimens, were analyzed. All isolates were amphotericin B, nystatin and micafungin sensitive, while 100% were clotrimazole, fluconazole and voriconazole resistant. Extracellular hydrolytic activities were detected in 52, 68 and 100% of the tested isolates for phospholipase, protease, and hemolysin, respectively, while CSH and biofilm production was shown in 24 and 20% of isolates, respectively. CSH had significant (p < /em> < 0.05) positive as well as negative associations with amphotericin B and fluconazole MICs, respectively. Source of clinical isolates showed significant (p < /em> < 0.05) influence on some resistance and virulence patterns. | ||||
| Keywords | ||||
| Candida albicans; resistance; Virulence; correlation; source | ||||
| References | ||||
|
1. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013; 4: 119-128.
2. Kauffman CA, Pappas PG, Sobel JD, Dismukes WE. Candidiasis. In: Vazquez JA, Sobel JD, editors. Essentials of Clinical Mycology. Springer-Verlag: New York; 2011, p. 167-206.
3. Lai CC, Wang CY, Liu WL, Huang YT, Hsueh PR. Time to positivity of blood cultures of different Candida species causing fungaemia. J Med Microbiol. 2012; 61(5): 701-704.
4. Ells R, Kilian W, Hugo A, Albertyn J, Kock JL, Pohl CH. Virulence of South African Candida albicans strains isolated from different clinical samples. Med Mycol. 2014; 52(3): 246-253.
5. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int J Microbiol. 2012; 2012: 1-14.
6. Basma R, Barada G, Ojaimi N, Khalaf RA. Susceptibility of Candida albicans to common and novel antifungal drugs, and relationship between the mating type locus and resistance, in Lebanese hospital isolates. Mycoses. 2009; 52(2): 141-148.
7. Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. Front Med. 2016; 3: 1-10.
8. Williams D, Lewis M. Oral Microbiology: Isolation and identification of Candida from the oral cavity. Oral Dis. 2000; 6(1): 3-11.
9. Al-Wasify RS. Sensitivity and specificity of chromogenic media for detection of some pathogens in water. Internet J Env Sustainable. 2013; 2(1): 1-9.
10. El-Houssaini HH, Elnabawy OM, Nasser HA, Elkhatib WF. Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. Microb Pathog. 2018; 128:13-19.
11. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard; CLSI document M27-A3. 2008; 28: 6-12.
12. Samaranayake L, Raeside JM, MacFarlane T. Factors affecting the phospholipase activity of Candida species in vitro. J Med Vet Mycol. 1984; 22(3): 201-207.
13. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia. 1982; 20(1): 7-14.
14. Staib F. Serum-proteins as nitrogen source for yeastlike fungi. Sabouraudia. 1966; 4(3): 187-193.
15. Deorukhkar S, Saini S. Virulence Markers and Antifungal Susceptibility Profile of Candida glabrata: An Emerging Pathogen. Br Microbiol Res J. 2014; 4: 39.
16. Manns JM, Mosser DM, Buckley HR. Production of a hemolytic factor by Candida albicans. Infect Immun. 1994; 62(11): 5154-5156.
17. Rosenberg M. Bacterial adherence to hydrocarbons: a useful technique for studying cell surface hydrophobicity. FEMS Microbiol Lett. 1984; 22(3): 289-295.
18. Kadam T, Rupa L, Balhal DK, Totewad ND, Gyananath G. Determination of the degree of hydrophobicity—a technique to assess bacterial colonization on the leaf surface and root region of lotus plant. Asian J Exp Sci. 2009; 23(1): 135-39.
19. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol. 2002; 40(4): 1244-1248.
20. Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP. Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol. 2003; 41(7): 2961-2967.
21. Brilhante RSN, Bittencourt PV, de Souza Collares Castelo‐Branco D, de Melo Guedes GM, de Oliveira JS, Alencar LP, et al. Biofilms of Candida spp. from the ocular conjunctiva of horses with reduced azole susceptibility: a complicating factor for the treatment of keratomycosis? Vet Ophthalmol. 2017;20: 539-546.
22. Kaur R, Goyal R, Dhakad MS, Bhalla P, Kumar R. Epidemiology and virulence determinants including biofilm profile of Candida infections in an ICU in a tertiary hospital in India. J Mycol. 2014; 2014: 303491.
23. Silva-Dias A, Miranda IM, Branco J, Monteiro-Soares M, Pina-Vaz C, Rodrigues AG. Adhesion, biofilm formation, cell surface hydrophobicity, and antifungal planktonic susceptibility: relationship among Candida spp. Front Microbiol. 2015; 6: 205.
24. Santa LA, Díaz LS, Illnait MZ, Perurena ML, de Francisco Cantelar N, Fernández CA. Susceptibility to nystatin of oral Candida isolates and its correlation with the response to treatment. Rev Cubana Med Trop. 2010; 62(3): 237-244.
25. Pfaller MA, Messer SA, Diekema DJ, Jones RN, Castanheira M. Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol. 2014; 52(1): 108-114.
27. Henry KW, Nickels JT, Edlind TD. Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors. Antimicrob Agents Chemother. 2000; 44(10): 2693-2700.
28. Paul S, Moye-Rowley WS. Multidrug resistance in fungi: regulation of transporter-encoding gene expression. Front Physiol. 2014; 5: 143.
29. Eraso E, Moragues MD, Villar-Vidal M, Sahand IH, González-Gómez N, Pontón J. Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species. J Clin Microbiol. 2006; 44(9): 3340-3345.
30. Deorukhkar SC, Saini S, Mathew S. Virulence factors contributing to pathogenicity of Candida tropicalis and its antifungal susceptibility profile. Int J Microbiol. 2014; 2014:1-6.
31. Udayalaxmi J, Shenoy N. Comparison between biofilm production, phospholipase and haemolytic activity of different species of Candida isolated from dental caries lesions in children. J Clin Diagn Res: JCDR. 2016; 10(4): DC21.
32. Sachin C, Ruchi K, Santosh S. In vitro evaluation of proteinase, phospholipase and haemolysin activities of Candida species isolated from clinical specimens. Int J Med Biomed Res. 2012; 1(2): 153-157.
33. Sacristan B, Blanco MT, Galan-Ladero MA, Blanco J, Perez-Giraldo C, Gomez-Garcia AC. Aspartyl proteinase, phospholipase, hemolytic activities and biofilm production of Candida albicans isolated from bronchial aspirates of ICU patients. Med Mycol. 2011; 49(1): 94-97.
34. Pannanusorn S, Fernandez V, Römling U. Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Mycoses. 2013: 56(3): 264-272.
35. Taylor BN, Fichtenbaum C, Saavedra M, Slavinsky III J, Swoboda R, Wozniak K. In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus. J Infect Dis. 2000; 182(3): 955-959.
37. Mesa-Arango AC, Rueda C, Román E, Quintin J, Terrón MC, Luque D. Cell wall changes in AmB-resistant strains from Candida tropicalis and relationship with the immune responses elicited by the host. Antimicrob Agents Chemother. 2016; AAC. 02681-15.
38. Graybill JR, Montalbo E, Kirkpatrick WR, Luther MF, Revankar SG, Patterson TF. Fluconazole versus Candida albicans: a complex relationship. Antimicrob Agents Chemother. 1998; 42(11): 2938-2942.
| ||||
|
Statistics Article View: 745 PDF Download: 728 |
||||
